Niklas Norén
Niklas Norén
Chief Science Officer, Uppsala Monitoring Centre, WHO Collaborating Centre for International Drug
Verified email at
Cited by
Cited by
Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers
G Hripcsak, JD Duke, NH Shah, CG Reich, V Huser, MJ Schuemie, ...
Studies in health technology and informatics 216, 574, 2015
Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery
GN Norén, J Hopstadius, A Bate
Statistical methods in medical research 22 (1), 57-69, 2013
Temporal pattern discovery in longitudinal electronic patient records
GN Norén, J Hopstadius, A Bate, K Star, IR Edwards
Data Mining and Knowledge Discovery 20, 361-387, 2010
Extending the methods used to screen the WHO drug safety database towards analysis of complex associations and improved accuracy for rare events
GN Norén, A Bate, R Orre, IR Edwards
Statistics in medicine 25 (21), 3740-3757, 2006
A statistical methodology for drug–drug interaction surveillance
GN Norén, R Sundberg, A Bate, IR Edwards
Statistics in medicine 27 (16), 3057-3070, 2008
vigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues
T Bergvall, GN Norén, M Lindquist
Drug safety 37, 65-77, 2014
Suspected adverse drug reactions reported for children worldwide: an exploratory study using VigiBase
K Star, GN Norén, K Nordin, IR Edwards
Drug safety 34, 415-428, 2011
Duplicate detection in adverse drug reaction surveillance
GN Norén, R Orre, A Bate, IR Edwards
Data Mining and Knowledge Discovery 14, 305-328, 2007
Good signal detection practices: evidence from IMI PROTECT
AFZ Wisniewski, A Bate, C Bousquet, A Brueckner, G Candore, K Juhlin, ...
Drug safety 39, 469-490, 2016
Current Safety Concerns with Human Papillomavirus Vaccine: A Cluster Analysis of Reports in VigiBase®
RE Chandler, K Juhlin, J Fransson, O Caster, IR Edwards, GN Norén
Drug safety 40, 81-90, 2017
Improved statistical signal detection in pharmacovigilance by combining multiple strength-of-evidence aspects in vigiRank: retrospective evaluation against emerging safety signals
O Caster, K Juhlin, S Watson, GN Norén
Drug safety 37, 617-628, 2014
Large‐scale regression‐based pattern discovery: the example of screening the WHO global drug safety database
O Caster, GN Norén, D Madigan, A Bate
Statistical Analysis and Data Mining: The ASA Data Science Journal 3 (4 …, 2010
Pneumonia may be more frequent and have more fatal outcomes with clozapine than with other second‐generation antipsychotics
J de Leon, EJ Sanz, GN Norén, C De las Cuevas
World Psychiatry 19 (1), 120, 2020
Recommendations for the use of social media in pharmacovigilance: lessons from IMI WEB-RADR
J van Stekelenborg, J Ellenius, S Maskell, T Bergvall, O Caster, ...
Drug Safety 42, 1393-1407, 2019
Impact of stratification on adverse drug reaction surveillance
J Hopstadius, GN Norén, A Bate, IR Edwards
Drug safety 31, 1035-1048, 2008
Temporal pattern discovery for trends and transient effects: its application to patient records
GN Norén, A Bate, J Hopstadius, K Star, IR Edwards
Proceedings of the 14th ACM SIGKDD international conference on Knowledge …, 2008
Bridging islands of information to establish an integrated knowledge base of drugs and health outcomes of interest
RD Boyce, PB Ryan, GN Norén, MJ Schuemie, C Reich, J Duke, ...
Drug safety 37, 557-567, 2014
Assessment of the utility of social media for broad-ranging statistical signal detection in pharmacovigilance: results from the WEB-RADR project
O Caster, J Dietrich, ML Kürzinger, M Lerch, S Maskell, GN Norén, ...
Drug safety 41, 1355-1369, 2018
Modern methods of pharmacovigilance: detecting adverse effects of drugs
GN Norén, IR Edwards
Clinical medicine 9 (5), 486, 2009
Performance of stratified and subgrouped disproportionality analyses in spontaneous databases
S Seabroke, G Candore, K Juhlin, N Quarcoo, A Wisniewski, R Arani, ...
Drug safety 39, 355-364, 2016
The system can't perform the operation now. Try again later.
Articles 1–20